Moody Aldrich Partners LLC Protagonist Therapeutics, Inc Transaction History
Moody Aldrich Partners LLC
- $475 Million
- Q4 2024
A detailed history of Moody Aldrich Partners LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Moody Aldrich Partners LLC holds 67,415 shares of PTGX stock, worth $2.37 Million. This represents 0.55% of its overall portfolio holdings.
Number of Shares
67,415
Previous 119,287
43.49%
Holding current value
$2.37 Million
Previous $5.36 Million
51.46%
% of portfolio
0.55%
Previous 1.07%
Shares
7 transactions
Others Institutions Holding PTGX
# of Institutions
254Shares Held
58.9MCall Options Held
226KPut Options Held
218K-
Farallon Capital Management LLC San Francisco, CA5.93MShares$208 Million1.22% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$202 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.5MShares$193 Million3.46% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$148 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$117 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.72B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...